Longeveron LLC - Asset Resilience Ratio

Latest as of December 2024: 0.00%

Longeveron LLC (LGVN) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check LGVN strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$0.00
Cash + Short-term Investments

Total Assets

$25.56 Million
All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2020–2024)

This chart shows how Longeveron LLC's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Longeveron LLC to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Longeveron LLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see LGVN company net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $0.00 0%
Total Liquid Assets $0.00 0.00%

Asset Resilience Insights

  • Limited Liquidity: Longeveron LLC maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company maintains a balanced mix of cash and short-term investments.

Longeveron LLC Industry Peers by Asset Resilience Ratio

Compare Longeveron LLC's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
Biotechnology -55.36%
Krystal Biotech Inc
NASDAQ:KRYS
Biotechnology 23.06%
Verona Pharma PLC ADR
NASDAQ:VRNA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
BB Biotech AG
SW:BION
Biotechnology 0.05%

Annual Asset Resilience Ratio for Longeveron LLC (2020–2024)

The table below shows the annual Asset Resilience Ratio data for Longeveron LLC.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.00% $0.00 $25.56 Million --
2023-12-31 3.41% $412.00K $12.08 Million -29.99pp
2022-12-31 33.40% $9.15 Million $27.41 Million +11.45pp
2021-12-31 21.95% $9.38 Million $42.77 Million --
2020-12-31 0.00% $0.00 $9.24 Million --
pp = percentage points

About Longeveron LLC

NASDAQ:LGVN USA Biotechnology
Market Cap
$25.33 Million
Market Cap Rank
#24670 Global
#5206 in USA
Share Price
$0.84
Change (1 day)
+9.09%
52-Week Range
$0.48 - $1.74
All Time High
$423.00
About

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; com… Read more